Ipamorelin | 2mg, 5mg & 10mg
Technical Specifications
- Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2 (Pentapeptide)
- Chemical Class: Selective Growth Hormone Secretagogue
- Format: Lyophilised Cake/Powder
- Purity: >99% (HPLC Verified)
- Endotoxin: <0.5 EU/mg (Suitable for sensitive in vitro assays)
- Solubility: High (Aqueous)
- Solvent: Solvent not included (Sold Separately)
- Grade: Analytical Research Grade
Variant Breakdown
- 2mg Vial: Contains 2mg Ipamorelin
- 5mg Vial: Contains 5mg Ipamorelin
- 10mg Vial: Contains 10mg Ipamorelin
Product Overview
Ipamorelin is a synthetic pentapeptide and a highly selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a).
In the landscape of Growth Hormone Releasing Peptides (GHRPs), Ipamorelin is unique due to its high specificity. Unlike GHRP-2 or GHRP-6, research demonstrates that Ipamorelin does not stimulate the release of Adrenocorticotropic Hormone (ACTH), Cortisol, or Prolactin, even at high saturation levels.
This "clean" pharmacological profile makes Ipamorelin the preferred reagent for researchers aiming to isolate the somatotropic (growth hormone) pathway without introducing the confounding variables of stress hormone elevation or appetite stimulation.
Quality Assurance
This compound has undergone rigorous third-party analysis.
- HPLC Verified: Independent analysis confirms peptide purity exceeds 99%.
- Mass Spectrometry: Confirms accurate molecular weight (approx. 711.9 g/mol) and amino acid sequence.
- TFA Removal: Processed via acetate exchange to remove inflammatory trifluoroacetic acid salts, ensuring high viability in sensitive cell culture applications.
Research Mechanism
In laboratory settings, Ipamorelin is utilised to investigate:
- Selective Secretion: The mechanism of GHS-R1a binding that triggers GH release without activating the HPA axis (cortisol).
- Bone Mineralisation: Studies examining the effect of pulsatile GH release on osteoblast function and bone density in animal models.
- Gastric Motility: Comparative research into why Ipamorelin lacks the strong orexigenic (hunger-inducing) side effects commonly seen with GHRP-6.
Safety and Handling
WARNING: This product is exclusively for laboratory research and in vitro use.
- Research Only: Not intended for human consumption, diagnostic, or therapeutic use.
- Handling: Wear appropriate personal protective equipment (PPE) including gloves and safety eyewear.
Storage: Store lyophilised vials in a cool, dry place. For long-term preservation, freezing at -20°C is recommended.
Scientific References
European Journal of Endocrinology (1998) – "Ipamorelin, the first selective growth hormone secretagogue." (The landmark study defining its selectivity). View Article
European Journal of Pharmacology (1999) – "Pharmacological characterisation of Ipamorelin, a new growth hormone secretagogue." View Article
Growth Hormone & IGF Research (1999) – "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats." View Article
